{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T04:00:25Z","timestamp":1778990425522,"version":"3.51.4"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Systemic mastocytosis (SM) is a disorder of excessive mast cell accumulation in tissues due to a somatic gain-of-function mutation, commonly in the KIT gene, which prevents apoptosis of mast cells. Whereas bone marrow, skin, lymph nodes, spleen and gastrointestinal tract are commonly involved, kidneys are rarely involved directly by SM. However, there are increasing reports of indirect kidney involvement in patients with SM. Novel anti-neoplastic agents to treat advanced forms of SM include non-specific tyrosine kinase inhibitors, which are reported to be associated with kidney dysfunction in some patients. SM is also associated with immune-mediated glomerulonephritis (GN) such as mesangioproliferative GN, membranous nephropathy and diffuse proliferative GN. Kidney injury, in the form of monoclonal deposition disease and primary light chain amyloidosis, is reported in SM associated with plasma cell dyscrasia. In this narrative review we discuss the various ways kidneys (and the urinary tract) are involved in patients with SM.<\/jats:p>","DOI":"10.1093\/ndt\/gfad081","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T05:43:20Z","timestamp":1682660600000},"page":"2456-2463","source":"Crossref","is-referenced-by-count":1,"title":["Kidney and urinary tract involvement in systemic mastocytosis"],"prefix":"10.1093","volume":"38","author":[{"given":"Joyita","family":"Bharati","sequence":"first","affiliation":[{"name":"Division of Kidney Diseases and Hypertension, Glomerular Center at Northwell Health, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , Great Neck, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikita","family":"Shah","sequence":"additional","affiliation":[{"name":"SUNY Polytechnic University , Utica, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankuri","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Northwell Health, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , Great Neck, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Gladstone","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, R J Zuckerberg Cancer Institute at Northwell Health, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , Great Neck, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandan","family":"Krushna Das","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology and Medical Oncology, Post Graduate Institute of Medical Education and Research , Chandigarh , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jacqueline","family":"Nieto","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, R J Zuckerberg Cancer Institute at Northwell Health, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , Great Neck, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-0524","authenticated-orcid":false,"given":"Kenar D","family":"Jhaveri","sequence":"additional","affiliation":[{"name":"Division of Kidney Diseases and Hypertension, Glomerular Center at Northwell Health, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , Great Neck, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6249-9837","authenticated-orcid":false,"given":"Hassan","family":"Izzedine","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Peupliers Private Hospital , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"2023103100562432200_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000085563","article-title":"Clonality and molecular pathogenesis of mastocytosis","volume":"114","author":"Akin","year":"2005","journal-title":"Acta Haematol"},{"key":"2023103100562432200_bib2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/bjh.12916","article-title":"Epidemiology of systemic mastocytosis in Denmark","volume":"166","author":"Cohen","year":"2014","journal-title":"Br J Haematol"},{"key":"2023103100562432200_bib3","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/jcp.2003.014860","article-title":"Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge","volume":"57","author":"Horny","year":"2004","journal-title":"J Clin Pathol"},{"key":"2023103100562432200_bib4","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"2023103100562432200_bib5","first-page":"62","article-title":"Mastocytosis","volume-title":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","author":"Horny","year":"2017"},{"key":"2023103100562432200_bib6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ajh.26118","article-title":"Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management","volume":"96","author":"Pardanani","year":"2021","journal-title":"Am J Hematol"},{"key":"2023103100562432200_bib7","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"2023103100562432200_bib8","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.4049\/jimmunol.1203420","article-title":"Innate immunity and its regulation by mast cells","volume":"190","author":"St John","year":"2013","journal-title":"J Immunol"},{"key":"2023103100562432200_bib9","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/ajcp\/84.6.710","article-title":"Adult-onset urticaria pigmentosa and systemic mast cell disease","volume":"84","author":"Travis","year":"1985","journal-title":"Am J Clin Pathol"},{"key":"2023103100562432200_bib10","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"2023103100562432200_bib11","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2013-01-453183","article-title":"How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage)","volume":"121","author":"Pardanani","year":"2013","journal-title":"Blood"},{"key":"2023103100562432200_bib12","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"key":"2023103100562432200_bib13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000504099","article-title":"The spectrum of aggressive mastocytosis: a workshop report and literature review","volume":"87","author":"Leguit","year":"2020","journal-title":"Pathobiology"},{"key":"2023103100562432200_bib14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.kint.2016.08.012","article-title":"An unusual case of tubulointerstitial renal mastocytosis","volume":"91","author":"Sanhueza","year":"2017","journal-title":"Kidney Int"},{"key":"2023103100562432200_bib15","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s11255-010-9878-5","article-title":"Systemic mastocytosis presenting with acute oliguric renal failure: report of a case and review of the literature","volume":"44","author":"Moore","year":"2012","journal-title":"Int Urol Nephrol"},{"key":"2023103100562432200_bib16","first-page":"63","article-title":"Mast cell ultrastructure and staining in tissue","volume":"315","author":"Shukla","year":"2006","journal-title":"Methods Mol Biol"},{"key":"2023103100562432200_bib17","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","article-title":"Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal","volume":"5","author":"Valent","year":"2021","journal-title":"Hemasphere"},{"key":"2023103100562432200_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12308-019-00367-7","article-title":"Systemic mastocytosis with renal light chain amyloidosis: associated non-mast cell disorder or concurrent disease","volume":"12","author":"Damlaj","year":"2019","journal-title":"J Hematopathol"},{"key":"2023103100562432200_bib19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ckj\/sfs104","article-title":"Indolent systemic mastocytosis associated with light chain deposition disease","volume":"5","author":"Sasaki","year":"2012","journal-title":"Clin Kidney J"},{"key":"2023103100562432200_bib20","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1097-0142(19880901)62:5<965::AID-CNCR2820620520>3.0.CO;2-M","article-title":"Significance of systemic mast cell disease with associated hematologic disorders","volume":"62","author":"Travis","year":"1988","journal-title":"Cancer"},{"key":"2023103100562432200_bib21","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies","volume":"114","author":"Pardanani","year":"2009","journal-title":"Blood"},{"key":"2023103100562432200_bib22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s002770050382","article-title":"A case of bone marrow mastocytosis associated with multiple myeloma","volume":"76","author":"Hagen","year":"1998","journal-title":"Ann Hematol"},{"key":"2023103100562432200_bib23","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1365-2141.1994.tb05115.x","article-title":"Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells","volume":"88","author":"Lemoli","year":"1994","journal-title":"Br J Haematol"},{"key":"2023103100562432200_bib24","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.clml.2012.08.002","article-title":"An unusual case of aggressive systemic mastocytosis with associated refractory plasma cell myeloma","volume":"12","author":"Jain","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2023103100562432200_bib25","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/modpathol.2010.224","article-title":"Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis","volume":"24","author":"Sotlar","year":"2011","journal-title":"Mod Pathol"},{"key":"2023103100562432200_bib26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.semarthrit.2006.03.004","article-title":"The role of mast cells in osteoporosis","volume":"36","author":"Chiappetta","year":"2006","journal-title":"Semin Arthritis Rheum"},{"key":"2023103100562432200_bib27","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1182\/blood-2017-12-824318","article-title":"Systemic mastocytosis with concurrent multiple myeloma","volume":"131","author":"Prabahran","year":"2018","journal-title":"Blood"},{"key":"2023103100562432200_bib28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1523-1755.2001.00783.x","article-title":"Role of stem cell factor and mast cells in the progression of chronic glomerulonephritides","volume":"60","author":"El-Koraie","year":"2001","journal-title":"Kidney Int"},{"key":"2023103100562432200_bib29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1600-065X.2007.00503.x","article-title":"Mast cells and inflammatory kidney disease","volume":"217","author":"Blank","year":"2007","journal-title":"Immunol Rev"},{"key":"2023103100562432200_bib30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0272-6386(98)70022-8","article-title":"Tubulointerstitial mast cell infiltration in glomerulonephritis","volume":"32","author":"Hiromura","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"2023103100562432200_bib31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1078\/0344-0338-00274","article-title":"Quantitative analysis of interstitial mast cells in AA and AL renal amyloidosis","volume":"198","author":"Danilewicz","year":"2002","journal-title":"Pathol Res Pract"},{"key":"2023103100562432200_bib32","first-page":"193","article-title":"Increased mast cell density in renal interstitium is correlated with relative interstitial volume, serum creatinine and urea especially in diabetic nephropathy but also in primary glomerulonephritis","volume":"58","author":"Oko\u0144","year":"2007","journal-title":"Pol J Pathol"},{"key":"2023103100562432200_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000322286","article-title":"Aggressive systemic mastocytosis associated with mesangioproliferative glomerulonephritis","volume":"125","author":"Diamantidis","year":"2011","journal-title":"Acta Haematol"},{"key":"2023103100562432200_bib34","first-page":"115","article-title":"Nephrotic syndrome in a patient with systemic mastocytosis","volume":"61","author":"Poliantseva","year":"1983","journal-title":"Klin Med"},{"key":"2023103100562432200_bib35","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0272-6386(88)80108-2","article-title":"Systemic mastocytosis associated with membranous nephropathy and peripheral neuropathy","volume":"12","author":"Lal","year":"1988","journal-title":"Am J Kidney Dis"},{"key":"2023103100562432200_bib36","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1172\/JCI111703","article-title":"Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis","volume":"75","author":"Remuzzi","year":"1985","journal-title":"J Clin Invest"},{"key":"2023103100562432200_bib37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/ki.1984.10","article-title":"Platelet-activating factor-induced loss of glomerular anionic charges","volume":"25","author":"Camussi","year":"1984","journal-title":"Kidney Int"},{"key":"2023103100562432200_bib38","doi-asserted-by":"crossref","first-page":"260","DOI":"10.5414\/CN110121","article-title":"Renal involvement and favorable outcome in a child with mastocytosis","volume":"94","author":"Cho","year":"2020","journal-title":"Clin Nephrol"},{"key":"2023103100562432200_bib39","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1093\/ckj\/sfab114","article-title":"Renal diseases secondary to interferon-\u03b2 treatment: a multicentre clinico-pathological study and systematic literature review","volume":"14","author":"Dauvergne","year":"2021","journal-title":"Clin Kidney J"},{"key":"2023103100562432200_bib40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000355753","article-title":"Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review","volume":"38","author":"Fabrizi","year":"2013","journal-title":"Kidney Blood Press Res"},{"key":"2023103100562432200_bib41","first-page":"109","article-title":"Broad spectrum of interferon-related nephropathies-glomerulonephritis, systemic lupus erythematosus-like syndrome and thrombotic microangiopathy: a case report and review of literature","volume":"8","author":"Gianassi","year":"2019","journal-title":"World J Nephrol"},{"key":"2023103100562432200_bib42","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2016-05-715987","article-title":"Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature","volume":"128","author":"Kavanagh","year":"2016","journal-title":"Blood"},{"key":"2023103100562432200_bib43","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.kint.2022.02.031","article-title":"Type I interferon-related kidney disorders","volume":"101","author":"Lodi","year":"2022","journal-title":"Kidney Int"},{"key":"2023103100562432200_bib44","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"2023103100562432200_bib45","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Alvarez-Twose","year":"2017","journal-title":"Oncotarget"},{"key":"2023103100562432200_bib46","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2022-167593","article-title":"An updated analysis on safety and efficacy of avapritinib in patients with advanced systemic mastocytosis from the explorer clinical study: long-term efficacy and safety","volume":"140","author":"DeAngelo","year":"2022","journal-title":"Blood"},{"key":"2023103100562432200_bib47","first-page":"1","article-title":"A severe case of acidosis with concomitant use of avapritinib and metformin requiring emergent hemodialysis","volume":"9","author":"Adio","year":"2020","journal-title":"Case Rep Int"},{"key":"2023103100562432200_bib48","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"2023103100562432200_bib49","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1634\/theoncologist.2018-0222","article-title":"FDA approval summary: midostaurin for the treatment of advanced systemic mastocytosis","volume":"23","author":"Kasamon","year":"2018","journal-title":"Oncologist"},{"key":"2023103100562432200_bib50","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s13730-020-00443-3","article-title":"Unique case of ANCA-negative pauci-immune necrotizing glomerulonephritis with diffuse alveolar hemorrhage, potentially associated with midostaurin","volume":"9","author":"Pankow","year":"2020","journal-title":"CEN Case Rep"},{"key":"2023103100562432200_bib51","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM199311183292106","article-title":"Brief report: tumor lysis syndrome following treatment with 2-chlorodeoxyadenosine for refractory chronic lymphocytic leukemia","volume":"329","author":"Dann","year":"1993","journal-title":"N Engl J Med"},{"key":"2023103100562432200_bib52","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJM199404143301517","article-title":"Tumor lysis syndrome after treatment of chronic lymphocytic leukemia with cladribine","volume":"330","author":"Trendle","year":"1994","journal-title":"N Engl J Med"},{"key":"2023103100562432200_bib53","doi-asserted-by":"crossref","DOI":"10.5301\/jo-n.5000008","article-title":"Acute tubular injury associated with imatinib (Gleevec): a case report and review of literature","author":"Barta","year":"2017","journal-title":"J Onc. Nephrol"},{"key":"2023103100562432200_bib54","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ekir.2016.09.055","article-title":"Adverse renal effects of novel molecular oncologic targeted therapies: a narrative review","volume":"2","author":"Jhaveri","year":"2017","journal-title":"Kidney Int Rep"},{"key":"2023103100562432200_bib55","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2215\/CJN.07311009","article-title":"Treatment with IFN-\u03b1, -\u03b2, or -\u03b3 is associated with collapsing focal segmental glomerulosclerosis","volume":"5","author":"Markowitz","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023103100562432200_bib56","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/01.COC.0000020649.11411.2B","article-title":"Interferon-alpha\u2013induced focal segmental glomerulosclerosis in chronic myelogenous leukemia: a case report and review of the literature","volume":"26","author":"Bremer","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"2023103100562432200_bib57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/10799900360520450","article-title":"Minimal change disease in a patient receiving IFN-\u03b1 therapy for chronic hepatitis C virus infection","volume":"23","author":"Dizer","year":"2003","journal-title":"J Interferon Cytokine Res"},{"key":"2023103100562432200_bib58","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/ndt\/16.4.846","article-title":"Renal thrombotic microangiopathy induced by interferon-\u03b1","volume":"16","author":"Badid","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"2023103100562432200_bib59","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00240-009-0198-0","article-title":"Ureteral stones due to systemic mastocytosis: diagnostic and therapeutic characteristics","volume":"37","author":"Molderings","year":"2009","journal-title":"Urol Res"},{"key":"2023103100562432200_bib60","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1464-410X.1996.20628.x","article-title":"Systemic mastocytosis: a possible aetiology of nephrolithiasis","volume":"78","author":"Manion","year":"1996","journal-title":"Br J Urol"},{"key":"2023103100562432200_bib61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000076585","article-title":"Osteoporosis and urolithiasis","volume":"72","author":"Caudarella","year":"2004","journal-title":"Urol Int"},{"key":"2023103100562432200_bib62","doi-asserted-by":"crossref","first-page":"e18028","DOI":"10.1200\/jco.2014.32.15_suppl.e18028","article-title":"Systemic mastocytosis manifested as chronic urinary symptoms for decades: a case report","volume":"32","author":"Poudel","year":"2014","journal-title":"J Clin Oncol"},{"key":"2023103100562432200_bib63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0094-0143(21)00590-5","article-title":"The role of the mast cell in interstitial cystitis","volume":"21","author":"Sant","year":"1994","journal-title":"Urol Clin North Am"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfad081\/50695681\/gfad081.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/11\/2456\/52661037\/gfad081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/11\/2456\/52661037\/gfad081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T06:26:00Z","timestamp":1698733560000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/38\/11\/2456\/7146207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":63,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,4,27]]},"published-print":{"date-parts":[[2023,10,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfad081","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,4,27]]}}}